NCT02148133View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 23, 2014

Primary Completion Date

September 10, 2015

Study Completion Date

September 5, 2017

Conditions
Cytopaenia
Interventions
DRUG

Eltrombopag 12.5 mg

White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet

DRUG

Eltrombopag 25 mg

White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet

Trial Locations (12)

453-8511

Novartis Investigative Site, Aichi

460-0001

Novartis Investigative Site, Aichi

664-8540

Novartis Investigative Site, Hyōgo

305-8576

Novartis Investigative Site, Ibaraki

920-8641

Novartis Investigative Site, Ishikawa

981-1293

Novartis Investigative Site, Miyagi

700-0962

Novartis Investigative Site, Okayama

530-0012

Novartis Investigative Site, Osaka

543-8555

Novartis Investigative Site, Osaka

565-0871

Novartis Investigative Site, Osaka

329-0498

Novartis Investigative Site, Tochigi

141-8625

Novartis Investigative Site, Tokyo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY